Specialty Finance / Healthcare Capital / Venture Debt
Strategic Profile
As a venture debt firm specializing in early-stage through growth-stage capital investments, SWK focuses on healthcare sectors including biopharma, medical devices, diagnostics, and life science tools, alongside technology and green energy/sustainability. SWK specializes in tailored capital solutions that preserve partners' ownership interests.
Cyborg Score Rationale
Revenue declined 19% year-over-year to $27.55 million in 2024, reflecting challenging market conditions in venture financing. However, Q2 2025 adjusted non-GAAP net income for the finance receivables segment grew to $4.6 million from $2.6 million year-over-year, and the company paid a $4.00 per share special dividend, indicating improved operational performance and capital return discipline.
Top Insights
SWK seeks to make investments between $5 million and $20 million, with ability to invest higher, positioning it in the mid-market life science financing niche
Enteris BioPharma subsidiary provides clinical development services and oral drug delivery formulation solutions based on its Peptelligence platform, creating diversification beyond pure finance
Company completed sale of royalty assets for $34 million and declared $4.00 per share special dividend, signaling portfolio optimization and shareholder capital returns
Market cap of approximately $208 million with recent 52-week trading range of $14.45-$18.10
Named Competitors
SVB Financial Group / SIVB Healthcare Lending — Venture debt and healthcare lending services